Lynley Marshall

From Wikipedia, the free encyclopedia

Lynley Marshall is a consultant in paediatric and adolescent oncology drug development at the Royal Marsden Hospital in London, where she leads the Paediatric and Adolescent Oncology Drug Development team.[1]

After completing her undergraduate training in Johannesburg, South Africa, and south west England, Marshall trained in paediatrics and then as a paediatric oncologist in University of Bristol and Oxford University. She holds a Ph.D. from the Institute of Cancer Research. [2]

Marshall chairs the National Cancer Research Institute Children's cancer and Leukaemia Clinical Studies Novel Agents Subgroup,[3] and is a member of the Innovative Therapies for Children with Cancer (ITCC) European Early Phase Trials Consortium.[4]

References[edit]

  1. ^ "Interview with Dr Lynley Marshall, Royal Marsden paediatric ECMC | ECMC". www.ecmcnetwork.org.uk. Retrieved 4 November 2022.
  2. ^ "Dr Lynley Marshall". Royal Marsden. Retrieved 16 September 2020.
  3. ^ "NCRI Groups". NCRI Groups. Retrieved 16 September 2020.
  4. ^ "ITCC Clinical Trial Committee". ITCC Clinical Trials Committee. Retrieved 16 September 2020.